Monoamine receptors and transporters

The monoamine system, encompassing serotonin, dopamine, and norepinephrine receptors and transporters, serves as a critical regulatory framework for neurotransmission within the central and peripheral nervous systems (StatPearls, 2023). This group includes a diverse array of proteins: the transporters (Sodium-dependent serotonin transporter [SLC6A4], Dopamine transporter [SLC6A3], and Norepinephrine transporter [SLC6A2]) which terminate signaling by reabsorbing neurotransmitters, and various receptor families (5-HT, D, and Adrenergic receptors) that initiate intracellular signaling cascades (IUPHAR/BPS, 2024). These molecules are essential for modulating mood, arousal, reward, motor control, and autonomic functions (NIH, 2022). Dysfunction in these pathways is implicated in a wide range of conditions, including major depressive disorder, ADHD, schizophrenia, and Parkinson's disease (PubMed, 2020). Pharmacological intervention typically involves reuptake inhibition to increase synaptic concentrations or direct receptor modulation to alter downstream signaling (NCBI, 2021). Due to their widespread expression, drugs targeting these proteins often require high selectivity to avoid off-target effects such as cardiovascular instability or movement disorders (StatPearls, 2023).

Other names

Serotonin, dopamine, and norepinephrine receptors and transportersMonoaminergic systemBiogenic amine receptors and transportersMonoamine neurotransmitter system

Drugs targeting this system act through several mechanisms: reuptake inhibition (blocking SERT, DAT, or NET to increase synaptic neurotransmitter levels), direct receptor agonism or antagonism (binding to GPCRs or ion channels to modulate downstream signaling), and enzymatic inhibition (e.g., inhibiting monoamine oxidase to prevent neurotransmitter degradation).